Physician profile
John R Harper
NPI 1720098205
$9,341.00
in general payments reported to CMS, 2019-2025
33 companies · $809 in 2025
The $809 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $1,435 · 2021: $2,258 · 2022: $1,573 · 2023: $820 · 2024: $898 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,677.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $742.99 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $520.54 | 2019-2023 | |
| Glaxosmithkline, LLC. | $515.04 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $482.48 | 2020-2022 | |
| Lilly USA, LLC | $465.81 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $403.89 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $388.82 | 2021-2023 | |
| Pfizer INC. | $380.54 | 2019-2025 | |
| Corcept Therapeutics | $374.68 | 2020-2024 | Korlym |
| Merck Sharp & Dohme LLC | $292.86 | 2019-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.67 | 2024-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $264.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $183.41 | 2019-2024 | |
| Amgen INC. | $156.63 | 2021-2024 | Repatha, Otezla, Evenity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $143.64 | 2021 | |
| Boston Scientific Corporation | $115.82 | 2019-2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $112.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $105.36 | 2019-2023 | Seglentis, Livalo |
| Xeris Pharmaceuticals, INC. | $101.08 | 2021-2025 | Recorlev |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2019 | |
| Astellas Pharma US INC | $96.68 | 2019-2021 | |
| Medtronic, INC. | $91.54 | 2021-2022 | |
| Zyla Life Sciences, INC. | $86.02 | 2019 | |
| Allergan, INC. | $55.94 | 2020 | |
| Shield Therapeutics INC | $52.61 | 2025 | |
| Janssen Pharmaceuticals, INC | $31.92 | 2019-2021 | |
| Sanofi Pasteur INC. | $24.85 | 2019-2021 | |
| Hologic Sales and Service, LLC | $19.86 | 2021 | |
| Medtronic Minimed, INC. | $19.15 | 2020 | |
| Sumitomo Pharma America, INC. | $18.47 | 2023-2024 | Gemtesa |
| Horizon Therapeutics Plc | $17.67 | 2020 | |
| Currax Pharmaceuticals LLC | $12.98 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.